Professional Overview
Alessio Ciulli is a renowned expert in chemical and structural biology, currently serving as the Founder and Director of the Centre for Targeted Protein Degradation (CeTPD) at the University of Dundee. His key expertise areas include targeted protein degradation, chemical biology, and structural biology, with a strong industry focus on drug discovery and development.
Experience Summary
Current Role
Alessio Ciulli is the Founder and Director of CeTPD, a position he has held since April 2021. As the Director, he oversees the overall strategy and direction of the centre, fostering collaboration between academics, industry partners, and clinicians to advance the field of targeted protein degradation. Key responsibilities include leading research initiatives, securing funding, and building strategic partnerships. Notable achievements include co-founding Amphista Therapeutics Limited, a company focused on developing novel therapeutics based on targeted protein degradation.
Career Progression
Alessio Ciulli's career trajectory demonstrates consistent growth and increasing responsibility. Notable previous roles include Professor of Chemical and Structural Biology at the University of Dundee, Reader and Principal Investigator at the University of Dundee, and BBSRC David Phillips Fellow and Group Leader at the University of Cambridge. His career progression highlights a strong commitment to research, leadership, and innovation.
Academic Background
Unfortunately, information on Alessio Ciulli's educational background is not provided.
Areas of Expertise
Alessio Ciulli's areas of expertise include chemical biology, structural biology, and targeted protein degradation. His technical competencies encompass a range of skills, including research design, team leadership, and collaboration. As a leader, he has demonstrated the ability to build and direct high-performing teams, secure funding, and drive innovation.
Professional Impact
Alessio Ciulli has made significant contributions to the field of targeted protein degradation, including co-founding Amphista Therapeutics Limited. His work has the potential to impact the development of novel therapeutics and improve human health. Measurable achievements include securing funding, publishing research papers, and presenting at conferences.
Conclusion
Alessio Ciulli's professional trajectory demonstrates a commitment to innovation, leadership, and research excellence. His current focus on targeted protein degradation has the potential to drive significant advancements in the field. As a leader and expert in his field, Alessio Ciulli offers a unique value proposition, combining scientific expertise with entrepreneurial spirit and a passion for improving human health.
